

Evaluation Of Prevalence And Clinical Profile Of Patients Of Metabolic Syndrome

Dr. Hemang Suthar*, Dr. Chintal Vyas*, Dr. Mayuri Singh**

*Associate Professor, Department Of Medicine, NHL Municipal Medical College, Ahmedabad, **Senior Resident, Department Of Medicine, AMC-MET Medical College, Ahmedabad

Abstract: Background: The metabolic syndrome is a highly prevalent condition among the patients with detrimental impact on short-term outcome. Early diagnosis, treatment including lifestyle modification and prevention of the metabolic syndrome may reduce the development of cardiovascular diseases like myocardial infarction including its complications. So, in this study we tried to find out prevalence of metabolic syndrome and study clinical profile, analyze biochemical parameters and study risk factors in patients with metabolic syndrome. Material And Methods: A prospective cross-sectional study was conducted in the department of medicine of tertiary care teaching hospital, Ahmedabad, India. Between August 2017 to August 2019. A total of 280 patients were selected randomly who visited the medical OPD. Diagnosis of Metabolic syndrome is based on: NCEP-ATP III 2001 (National cholesterol Education Program Adult Treatment Panel III). A detailed medical history of the patient including symptomatology, details of past illness, occupation, habits (smoking and alcohol) was obtained. A complete physical examination and systemic examination was performed. Results were expressed as mean± SD for continuous data and were compared by chi square test between two groups. Result: Out of the 280 cases, metabolic syndrome was present in 184 cases with incidence of 65.72%. 30% of males and 70% of females had metabolic syndrome. Mean age of metabolic syndrome in was 58 (57.84+11.35) years with age of patients ranged from 20 to 85 years with maximum number of cases were in the 51-60 years age group (33.2%). The most common mode of presentation in metabolic syndrome group was chest pain 45 (24.5%), followed by headache, 41 (22.3%), gabharaman, 29 (15.8%), fatigability, 29 (15.8%), and giddiness, 28 (15.2%). 31.5%, 22.3% and 22.8% of metabolic syndrome patients had past history of diabetes mellitus, hypertension and IHD respectively. In patients with metabolic syndrome, mean values of fasting blood glucose, serum triglyceride level, systolic blood pressure were 155.19mg/dl, 179.16mg/dl, 143.43 mm of Hg respectively. In patients with metabolic syndrome mean values of hdl level were 31.29mg/dl and 39.29mg/dl in male and females respectively. The most common biochemical abnormality was found to be increased triglyceride levels followed by increased fasting blood sugar. Conclusion: Early diagnosis, treatment including lifestyle modification and prevention of the metabolic syndrome may reduce the development of cardiovascular diseases like myocardial infarction including its complications. So, cardiovascular disease patients with metabolic syndrome must be identified and managed aggressively to reduce both morbidity and mortality. In this study, metabolic syndrome was more common amongst women who can be particularly attributed to high BMI, low HDL and increased waist circumference. [Suthar H Natl J Integr Res Med, 2021; 12(6): 40-47]

Key Words: Metabolic Syndrome, High Blood Pressure, Increased Triglyceride, Hyperglycemia

Author for correspondence: Dr. Chintal Vyas, Associate Professor, Department Of Medicine, NHL Municipal Medical College, Ahmedabad E-Mail: chintalvyas@gmail.com

Introduction: Metabolic syndrome is the term given to address a collection of risk factors. These risk factors are considered to increase risk for diabetes mellitus, coronary artery disease and cerebrovascular accident¹. These diseases in turn lead to adverse outcomes causing 1.6 times increase in mortality. The Metabolic syndrome is a specific clustering of cardiovascular risk factors (central obesity, dyslipidemia, hypertension, glucose intolerance, a prothrombotic state and a proinflammatory state)²⁻⁴. Obesity and resistance to insulin are found to be mainly caused by absence of physical work, sedentary lifestyle and poor dietary habits like fatty foods. Studies have

revealed the pathophysiology of this syndrome, with close to a sixfold increase in cardiovascular mortality in those possessing this disorder⁵. The increased risk of morbidity and mortality associated with the metabolic syndrome makes it essential that there be a clear understanding of the dimensions of this syndrome for the allocation of health care and research resources⁶.

The guidelines issued by Adult Treatment Panel III(ATP-III) of National Cholesterol Education Program (NCEP)used to diagnose includes resistance to insulin, elevated blood pressure, elevated lipid profile and obesity⁷. All

This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for any purpose, even commercially, provided the original work is properly cited and states its license.

components of metabolic syndrome are mostly preceded by obesity. At least 3 out of five components are necessary to make a diagnosis of metabolic syndrome. Ethnic and national specificity is required for waist circumference.

Genetics, ageing, state of inflammation and changes in hormone may also have a causal effect, but the role of these may vary depending on ethnic group. Certain risk factors that are non-classic like C - reactive protein, abnormal oxidized low-density lipoprotein-cholesterol and adiponectin are very much related to metabolic syndrome.

From a practical clinical perspective and also from a clinical standpoint people at high metabolic risk are identified by using the metabolic syndrome criteria⁸. A high level of low-density lipoprotein-cholesterol which is a traditional risk factor may be absent and so the individuals at high risk might be overlooked if these metabolic syndrome criteria are not utilized.

As metabolic syndrome being the important factor leading to two major diseases, cardiovascular diseases and type 2 diabetes, there is an immense need on social, moral and on medical perspective for early detection of people with metabolic syndrome. Thus, the onset of diseases like diabetes, cardiovascular disease can be prevented very well by identifying metabolic syndrome earlier. These people can be advised and subjected to lifestyle modifications and started on appropriate treatment⁹⁻¹¹. Thus, metabolic syndrome is helpful in rapid identification of people at high metabolic risk.

This study is undertaken to identify and assess the prognosis of metabolic syndrome by clinical and biochemical parameters as factors individuals.

Material & Methods: A prospective cross-sectional study was conducted in the department of medicine of department of medicine of tertiary care teaching hospital, Ahmedabad, India, between August 2017 to August 2019. A total of 280 patients were selected randomly who visited the medical OPD during the study years. Patients satisfying inclusion criteria were taken for the study. They were briefed about the study and their informed consent was taken. National Cholesterol Education Program Adult Treatment

Panel III (ATP III) criteria was used to define metabolic syndrome in the study group. All patients selected underwent a thorough clinical examination and laboratory examination pertaining to metabolic syndrome.

Inclusion Criteria: Patients more than 20 years of age who consented for the study. Patients who were willing for regular follow up.

Exclusion Criteria: Patients aged <20 years. Patients who were pregnant. Patients not willing to participate in study. Patients with critical illness in the form of renal failure, liver failure, acute myocardial infarction, carcinoma. The confirmed cases for the study were finally analyzed and assessed clinically and by appropriate laboratory investigations.

Sample Size: Sample size was calculated by the help of prevalence rate obtained from a recent study in Gujarat (2015)¹²

Formula Used: $N = (Z_{1-\alpha})^2 [P(1-P)/D^2]$, where N=sample size, 1- α = confidence interval which is taken as 95%, P= prevalence, D= absolute precision required which is taken as 5%.

On applying the above mentioned formula the sample size was taken as 280. A detailed medical history of the patient including symptomatology, details of past illness, occupation, habits (smoking and alcohol) was obtained. A complete physical examination and systemic examination was performed.

Diagnosis of Metabolic syndrome is based on: NCEP-ATP III 2001 (National cholesterol Education Program Adult Treatment Panel III).

Definition of metabolic syndrome¹³ includes: Three or more of the following:

- Central Obesity: waist circumference > 102 cm (40 in) male or > 88 cm (35 in) female.
- Hypertriglyceridemia: TGs \geq 150mg/dl (\geq 1.7 mmol/L)
- HDL Cholesterol: < 40mg/dl(male) or <50mg/dl(female)
- Hypertension: BP \geq 130 /85 mmHg or specific medication.
- Fasting plasma glucose \geq 110mg% (\geq 5.6mmol/L) or on specific medication.

IDF Guidelines: Abdominal obesity as defined by waist circumference of ≥ 90 cm for men and ≥ 80 cm for female specific for South Asians was used. Metabolic syndrome score ≥ 3 were taken as having metabolic syndrome in this study.

Sitting blood pressure was measured in brachial arteries of both arms with an appropriate mercury sphygmomanometer after 10 minutes of resting and the average of 2 systolic and diastolic blood pressures was taken. If a high BP was recorded then it was repeated and 3rd time blood pressure was taken after 30 mins and lowest of them was recorded finally.

Each patient's anthropological measurements were obtained with emphasis on height, weight, waist circumference, body mass index (BMI).

Waist girth was measured at a half way distance between anterior ischial crest and lower rib margin with full abdominal relaxation. Standing hip girth was taken. Girth measured at intertrochanter level. Weight was measured in KGs (kilograms) using calibrated weighing scale.

Height was measured in cm (centimeters) without footwear in standing position. BMI was calculated by dividing weight by height squared (kg/m^2).

Venous blood was collected in evacuated tubes after an overnight fast of 8-12 hours for serum triglycerides, hdl cholesterol, ldl cholesterol and fasting blood glucose levels. Individuals taking antihypertensive or statins or other lipid lowering agents were classified as having hypertension and dyslipidemia. Individuals taking insulin or oral hypoglycemic medications were classified as having diabetes.

Individuals who have been diagnosed as hypertension and diabetes but did not take any medications were not classified as having hypertension and diabetes. ECG was taken according to standard method and calibrated instruments after resting of patient. Results were expressed as mean \pm SD for continuous data and were compared by chi square test between two groups. A p value of 0.05 or less was considered for statistical significance.

Results: In out of the 280 cases, metabolic syndrome was present in 184 cases with incidence of 65.72%. Out of the 280 cases, 118(42.0%) were males and 162(58%) were

females; 30% of males and 70% of females had metabolic syndrome. The incidence of metabolic syndrome was more common in females who were 129(70.1%) when compared to males who were 55(29.9%) which was statistically significant ($p < 0.0001$). Mean age of metabolic syndrome in our study group was 58 (57.84 ± 11.35) years with age of patients ranged from 20 to 85 years.

Maximum numbers of cases were in the 51-60 years age group (33.2%) followed by 41-50 years, 51(27.7%). Female cases predominated in group with metabolic syndrome (70%).

Results were expressed as mean SD for continuous data and were compared by chi square test between two groups.

In present study, the most common mode of presentation in metabolic syndrome group was chest pain 45 (24.5%), followed by headache, 41 (22.3%), gabbaraman, 29 (15.8%), fatigability, 29 (15.8%), and giddiness, 28 (15.2%).

Breathlessness, 18 (19.8%), weight gain, 11 (6.0%), polyuria/polyphagia, 11 (6%) were less common presentations. The past history of diabetes mellitus 58 (31.5%), hypertension 41 (22.8%) and history of ischemic heart disease 42 (22.8%) were more common in the metabolic syndrome group compared to those without metabolic syndrome who had past history of DM were 18 (18.8%), Hypertension were 10 (10.4%) and IHD were 9 (9.4%) and was significant statistically (p value < 0.05).

In metabolic syndrome patients, there were 36 (19.6%) patients who smoked and 16 (16.7%) patients had history of alcohol consumption. In patients of metabolic syndrome, all the components such as FBS ≥ 110 mg% 119(42.5%), BP $\geq 130/85$ mm Hg 97 (34.64%), serum triglyceride ≥ 150 mg/dl 135 (48.21%), HDL < 40 mg/dl [(M) 34(12.14%) and < 50 mg/dl (F) 111 (39.64%)], WC ≥ 90 cm [(M) 43 (15.36%) and WC ≥ 80 cm (F) 119 (42.5%)] were more common than patients without it and were strongly significant ($p < 0.0001$). Out of 280 cases, 139 cases had their blood pressure in the metabolic syndrome range. 97 cases with metabolic syndrome had blood pressure of above 130/85 mm of hg. In them 63 cases were female and 34 were males. Higher number of hypertensive patients with metabolic syndrome was found to be statistically significant.

Out of 280 cases in the present study, 160 (103 females, 57 males) had serum triglycerides in the syndrome. Higher number of patients with increased triglycerides had metabolic syndrome and was found to be statistically significant than non-metabolic group. In present study of 280 cases, 182 cases had their fasting blood sugar in the metabolic syndrome range. Out of 182 cases, 136 (42.5%) had metabolic syndrome. In 136 cases, 37 were male and 99 were female.

Maximum number of females with metabolic syndrome fell in impaired fasting glucose 45 (35%) and diabetes mellitus 44 (34%). Maximum number of males were in the diabetes mellitus group 27 (49%) followed by cases in normoglycemia 18 (32.7%). Higher number of patients with increased FBS in metabolic syndrome as compared to non-metabolic syndrome was statistically significant.

metabolic syndrome range. Out of the above 160, 135 (96 females, 39 males) had metabolic syndrome. Out of 280 cases, 189 cases had HDL in the metabolic syndrome range out of which 104 cases had metabolic syndrome. Females with metabolic syndrome were 70 (54.2%) who had HDL <40mg/dl while the number of male cases were 34 (61%).

Among the components of metabolic syndrome fbs \geq 110 mg% (42.5) was the most prevalent component in both the groups (42.5% in metabolic syndrome and 32% in without metabolic syndrome groups), followed by high triglycerides (48.21%) and high waist circumference in females (42.5%), low hdl (39.64) in females, hypertension (34.64%) or and high waist circumference in males (15.36%), in that order and was significant statistically.

Table 1: Demographic Profile Of Patients Of Metabolic Syndrome

Gender	Metabolic Syndrome (N=184)	No Metabolic Syndrome (N=96)	No Of Patients (N=280)	P Value
Male	55(29.9%)	63(65.6%)	118(42.1%)	<0.0001
Female	129 (70.1%)	33 (34.4%)	162 (57.9%)	
SYMPTOMS				
Chest Pain	45 (24.5%)	33 (34.4%)	78 (27.9%)	0.1512
Headache	41 (22.3%)	15 (15.6%)	56 (20.0%)	0.1629
Giddiness	28 (15.2%)	12 (12.5%)	40 (14.3%)	0.9425
Gabharaman	29 (15.8%)	14 (14.6%)	43 (15.4%)	0.9652
Fatigability	29 (15.8%)	12 (12.5%)	41 (14.6%)	0.5142
Breathlessness	18 (9.8%)	14 (14.6%)	32 (11.4%)	0.2017
Weight Gain	11 (6.0%)	9 (9.4%)	20(7.1%)	0.5692
Polyuria/Polyphagia	11 (6.0%)	2 (2.1%)	13 (4.6%)	0.3182
Risk Factor				
H/O Dm	58 (31.5%)	18 (18.8%)	76 (27.1%)	0.0412
H/O Htn	41 (22.3%)	10 (10.4%)	51 (18.2%)	0.0131
Ihd	42 (22.8%)	9 (9.4%)	51 (18.2%)	0.0042
Smoking	36 (19.6%)	16 (16.7%)	52 (18.6%)	0.4245
Alcohol	12(6%)	10(10.41%)	22(7.8%)	0.3597
Components Of Metabolic Syndrome				
FBS \geq 110MG%	119 (42.5%)	32 (11.43%)	151(53.93%)	0.0006
BP \geq 130/85 MM HG	97 (34.64%)	42 (15%)	139 (49.64%)	<0.0001
TGS \geq 150MG/DL	135 (48.21%)	26(9.29%)	161 (57.5%)	0.0014
HDL <40MG/DL (M)	34 (12.14%)	27 (9.64%)	61 (21.79%)	<0.0001
HDL <50MG/DL (F)	111 (39.64%)	17 (6.07%)	128 (45.71%)	<0.0001
WC \geq 90CM (M)	43 (15.36%)	25 (8.93%)	68 (24.29%)	<0.0001
WC \geq 80CM (F)	119 (42.5%)	21 (7.5%)	140 (50.0%)	<0.0001

Table 2: Age Wise Distribution Of Patients

Age (Years)	Metabolic Syndrome (N=184)	No Metabolic Syndrome (N=96)	No Of Patients (N=280)
21-30	3 (1.6%)	1 (1%)	4 (1.4%)
31-40	2 (1.1%)	3 (3.1%)	5 (1.8%)
41-50	51 (27.7%)	33 (34.4%)	84 (30%)
51-60	61 (33.2%)	25 (26%)	86 (30.7%)
61-70	48 (26.1%)	20 (20.8%)	64 (24.3%)
71-80	13 (7.1%)	11 (11.5%)	24 (8.6%)
>81	6 (3.3%)	3 (3.1%)	6 (3.2%)
Mean Age	58.12 ± 11.12	57.29 ± 11.84	57.84 ± 11.35
P Value	0.5623		

Table 3: Mean Values Of Parameters Of Metabolic Syndrome In Patients

Risk Factor	Metabolic Syndrome (N=184)	No Metabolic Syndrome (N=96)	P Value
FBS (mg/dl)	155.19 ± 65.62	137.28 ± 21.63	0.0010
Blood pressure (mm Hg)	143.43 ± 13.89	135.85 ± 22.18	<0.0001
Triglyceride (mg/dl)	179.16 ± 25.09	178.12 ± 22.17	<0.0001
HDL mg/dl (Male)	31.29 ± 5.83	33.03 ± 6.16	<0.0001
HDL mg/dl (Female)	39.29 ± 6.78	34.29 ± 8.60	<0.0001
Waist circumference in cm (Male)	99.74 ± 5.42	95.44 ± 4.90	0.0236
Waist circumference in cm (Female)	84.36 ± 7.00	90.23 ± 10.17	0.0247

Table 4: Correlation Of IHD And RBS With Metabolic Syndrome

Other Risk Factor	Metabolic Syndrome Odds Ratio	P Value
RBS	1.27 (1.08 - 1.27)	0.0012
Ischemic Heart Disease	0.75 (0.64 - 0.87)	0.0013

In the present study, it was found that parameters such as responsible risk factors of ischemic heart disease and RBS had strong correlation with metabolic syndrome which indicated that independent predictor of CVD mortality in patients with type 2 DM.

Discussion: In the present study, the overall prevalence of metabolic syndrome is 65% which is comparable with study done by Srinivasan et al²⁰ in which it is 60.9%. In the present study, maximum number of patients having metabolic syndrome were in the age group of 51-60 years, i.e., 61 patients (33.2%) followed by 41-50 years

i.e., 51 patients (27.7%) The mean age was found to be 58.12 years which is comparable to J kaur et al¹⁴ in which it was 52.3 years. In our study the females predominated in metabolic syndrome group i.e., 129 (70.1%). Raised BMI, lower level of HDL and increased waist circumference might be the probable reason for the increased occurrence of metabolic syndrome in females. In our study past history of diabetes mellitus (31.5%), hypertension (22.3%) and ischemic heart disease (22.8%) were present. When compared to other studies known diabetic patients, 58 (31.5%) was comparable to study done by Saikat et al²¹ in which it was found 31.5.

Table 5: Comparison Of Various Components In Metabolic Syndrome Patients In Different Studies

Study	FBS(>=10mg/dl)	BP (>=130/85mm of Hg)	TGs(>=150mg/dl)	HDL-C (<=50(F), <=40mg/dl, M)	WC (>=90cms M, >=80 cms F)
Rothangpui et al ¹⁹	53%	73%	73%	43%	100%
RK Kotokeyb et al ¹⁶	71.5%	37.5%	30%	50.5%	100%
Present study	42.5 %	34.64%	48.21%	52.9%	57.86%

All the components were more common in metabolic syndrome group compared to those

without Metabolic Syndrome and were statistically significant. Blood pressure >130/85

mm of hg (34.64%) and HDL-C level <50 mg/dl in female and <40mg/dl(52.9%) were comparable to R K Kotokey et al¹⁶ in which it was found 37.5% and 50.5% respectively. In the present study, 15.36% of males and 42.5% females with a total of 57.86% had a waist circumference fulfilling the criteria of metabolic syndrome. It is comparable to the study done by RK Kotokey et al¹⁶. In the present study, the higher waist circumference may reflect the increasing burden of obesity in the current society keeping in mind the increasing prevalence of sedentary lifestyle.

In the present study, 10(6 females,4 males) cases of metabolic syndrome fell under underweight category while 50 cases had normal BMI (25 males and females). 42 (30 female and 12 male) cases came under overweight and 94 cases were obese (68 females and 26 males). Maximum numbers of patients were in overweight and obese category. In the present study 72% patients of metabolic syndrome were either overweight or obese.

In the present study out of 280 cases, 139 cases had their blood pressure in the metabolic syndrome range. 97 cases with metabolic syndrome had blood pressure of above 130/85 mm of hg. In them 63 cases were female and 34 were males. While 66 females and 21 males with metabolic study had blood pressure of <120/80 mm of hg.

In the present study the mean systolic blood pressure was 143.43mm Hg \pm 13.89, while the diastolic blood pressure was 86mmHg \pm 9.66. This was higher than the study done by Srinivasan et al²⁰ where the mean systolic blood pressure 136.2 mm Hg \pm 15.9 and diastolic blood pressure was 88.2mmHg \pm 9.3. In the present study, out of 280 cases, 182 cases had their fbs in the metabolic syndrome range. Out of 182 cases, 136 (42.5%) had metabolic syndrome. In 136 cases, 37 were male and 99 were female. Maximum number of females with metabolic syndrome fell in impaired fasting glucose 45 (35%) and diabetes mellitus 44 (34%). Maximum number of males were in the diabetes mellitus group 27(49%) followed by cases in normoglycemia 18 (32.7%). The mean FBS in metabolic syndrome cases is 155.19 \pm 65.62.

In our study, 81 patients (35.5%) had fasting blood sugar greater than 125mg/dl and were

hence newly diagnosed Diabetes Mellitus II patients. 55 patients (45%) had impaired fasting glucose and were hence at an increased risk of developing DM II which is comparable to Ramachandran A et al²² in which the values were 45.4% and 26.7% respectively. Only 58 patients with metabolic syndrome have fasting blood glucose in the normal Range. In the present study, there are increased number of patients in the pre-diabetic range and lesser in the normoglycemic range compared to the previous study, reflecting increased burden of undiagnosed patients mainly because of the decreased awareness about the magnitude about the problem that diabetes is and also because a major part of the patient come from a lower socioeconomic-class. Lesser number of patients in the normoglycemic range may reflect the increasing incidence of DM II in the current society

In the present study of 280 cases, 184(65.7%) cases had HDL in the metabolic syndrome range out of which 104 cases had metabolic syndrome. Females with metabolic syndrome were 70 (54.2%) who had HDL <40mg/dl while the number of male cases were 34 (61%). 19 (15%) females and 14 (21%) males with metabolic syndrome had normal HDL levels. This is comparable to the Franklin Study in which 72.9% of males and 75.52% of females fulfilled the definition criteria²³. However, there are a greater number of patients with HDL <40 mg/dl and 40-49mg/dl which can be explained by the lack of proper exercise in the current study population.

In the study done by Gupta R¹⁷ 90.2% of females and 54.5% of males have low levels of serum HDL, while Gupta A¹⁵ did the study in which 54.9% of males and 90.2% of females had HDL values fulfilling the definition criteria. Both the study i.e., by Gupta A and by Gupta R is comparable to the present study. The study done by Ramachandran et al²² (N=475) had total of 65.5% of the population with low HDL values which is comparable to the present study. This may be because of the current sedentary lifestyle of the patients with lack of regular exercise. Out of 280 cases in the present study, 160 (103 females,57 males) had serum triglycerides in the metabolic syndrome range. Out of the above 160, 135 (96 females, 39 males) had metabolic syndrome. 49 (33 females, 16 males) cases of metabolic syndrome had normal triglyceride levels. In the present study 73.6% females and

71% males had elevated values of serum triglycerides level.

Conclusion: In present study, metabolic syndrome was more common amongst women which can be particularly attributed to high BMI, low HDL and increased waist circumference. The most common biochemical abnormality was found to be increased triglyceride levels followed by increased fasting blood sugar. Early diagnosis, treatment including lifestyle modification and prevention of the metabolic syndrome may reduce the development of cardiovascular diseases like myocardial infarction including its complications. So, cardiovascular disease patients with metabolic syndrome must be identified and managed aggressively to reduce both morbidity and mortality.

References:

1. Robert H. Eckel. The metabolic syndrome, Harrison's Principles of Internal Medicine. 17th edition. New York, McGraw- Hill 2008; 1509-1513.
2. Robert F. Kushner. Evaluation and Management of Obesity. Harrison's Principles of Internal Medicine. 17th edition. New York, McGraw- Hill 2008; 468-473.
3. Third report of the National Cholesterol Education Program (NCEP) Expert panel on Detection, Evaluation, and Treatment of high blood cholesterol in adults (Adult Treatment Panel III) Final report. *Circulation* 2002; 106: 3146-3421.
4. Milani RV, Lavie CJ. Prevalence and profile of metabolic syndrome in patients following acute coronary events and effects of therapeutic life style change with cardiac rehabilitation. *Am J Cardiol* 2003; 92(1): 50-54.
5. Haffner SM. The metabolic syndrome: Inflammation, Diabetes mellitus, and Cardiovascular disease. *Am J Cardiol* 2006; 97(suppl): 3A-11A.
6. Ford EA, Giles WH. A comparison of the prevalence of the metabolic syndrome using Two Proposed Definitions. *Diabetes Care* 2003; 26: 575-581.
7. Expert Panel on Detection E. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). *Jama*. 2001 May 16;285(19):2486.
8. Daniel J. Radar, Hellen H. Hobbs Disorders of Lipoprotein metabolism. Harrison's Principles of Internal Medicine. 17th edition. New York, McGraw-Hill 2008 ; 2416-2429.
9. Munjal YP, Sarena A. Metabolic syndrome: Assessing Cardiometabolic risk, Chapter 50: In YP Munjal, Post-graduate medicine (Recent Advances in Medicine): JP Publishers: 2007; XXI: 461.
10. Deepa R, Shanthirani S, Premalatha G, Sastry NG, Mohan V. Prevalence of insulin resistance syndrome in a selected south Indian population. The Chennai urban population study-7 (CUPS-7). *Indian J Med Res* 2002; 115-118-127.
11. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide population. *Endocrinol Metab Clin North Am* 2004; 33: 351-75.
12. Prasad DS, Kabir Z, Dash AK, Das BC. Prevalence and risk factors for metabolic syndrome in Asian Indians: A community study from urban Eastern India. *J Cardiovasc Dis Res* 2012;3:204-11.
13. Ford ES. Prevalence of the metabolic syndrome in US population. *Endocrinol Metab Clin N Am* 2004; 33: 333-350.
14. Kaur J. Assessment and screening of the risk factors in metabolic syndrome. *Medical Sciences*. 2014 Jul 11;2(3):140-52.
15. Gupta A, Gupta r, Sama M, Rastogi S, Gupta VP, Kothari K. Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population. *Diab Res Clin Pract* 2003; 61:69-76
16. Kotokey RK, Kalita D, Agarwala R, Purkayastha S. Prevalence of Metabolic Syndrome in urban population of Dibrugarh town of upper Assam. *Journal of Indian College of Cardiology*. 2013 Jun 1;3(2):52-6.
17. Gupta R, Deedwania PC, Gupta A, Rastogi S, Panwar R B, Kothari K. Prevalence of metabolic syndrome in Indian urban population ; *Int J Cardiol*, 2004 Nov : 257-61
18. V Agarwal, M Bansal, R Mehrotra, G Hansa, R R Kasliwal; Prevalence of metabolic syndrome in an asymptomatic urban North Indian population : *Indian Heart Journal*, Sept 2003:90
19. Rothangpui, Thiyam G, Joute Z. Clinical profile in metabolic syndrome. *Int J Sci Rep* 2015;1(5):220
20. Srinivasan S *Int Jour Adv Medicine* 2016 Nov: 3(4) : 898-904

21. Kanjilal S, Shanker J, Rao VS, et al. Prevalence and component analysis of metabolic syndrome: an Indian atherosclerosis research study perspective. *Vasc Health Risk Manag.* 2008;4(1):189-197.
22. Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Metabolic syndrome in Urban Asian Indian adults- A population study using modified ATP III criteria. *Diab Res Clin Pract* 2003; 60: 199-204
23. Franklin SS, Wong ND, Pio J, et al. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. *Am J Cardiol* 2003;91:1421-6.

Conflict of interest: None
Funding: None
Cite this Article as: Suthar H, Vyas C, Singh M. Evaluation Of Prevalence And Clinical Profile Of Patients Of Metabolic Syndrome. <i>Natl J Integr Res Med</i> 2021; Vol.12(6): 40-47